Synlogic presents synb8802 for enteric hyperoxaluria at the american institute of chemical engineers conference on microbiome engineering

Cambridge, mass., dec. 7, 2020 /prnewswire/ -- synlogic, inc. (nasdaq: sybx), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present additional translational and in silico data on synb8802, a synthetic biotic...
SYBX Ratings Summary
SYBX Quant Ranking